Cytek Anticipates 2024 Revenue Between $200M-$201M, 4% Growth Over 2023; Q4 Revenue Expected At $57M-$58M, 11%-13% Rise from Q3 Amid $1.5M Impact from Stronger USD.

Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024.

Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cytek's 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million. Expected fourth quarter revenue of $57 million to $58 million represents growth of 11% to 13% compared to the third quarter of 2024 and decline of 2% to flat compared to a strong fourth quarter of 2023. The appreciation of the US dollar negatively affected fourth quarter revenue by approximately $1.5 million.